Measuring how PD-L1 therapies work in tumors without invasive procedures
Non-invasive Quantification of Dose-Exposure-Response of PD-L1 Therapeutics at the Tumor
This study is looking for a new, easy way to see how well certain cancer treatments are working for people with non-small cell lung cancer by checking the levels of a specific protein in their tumors, which could help doctors choose the best treatment for each patient.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10447016 on NIH RePORTER |
What this research studies
This research aims to develop a non-invasive method to measure the effectiveness of PD-L1 therapeutic antibodies in treating non-small cell lung cancer (NSCLC). By assessing the levels of PD-L1 and the engagement of these antibodies at the tumor site, the study seeks to improve patient stratification for immunotherapy. The approach involves real-time monitoring of drug-target interactions, which could lead to better predictions of treatment efficacy for individual patients. This innovative technique addresses the current challenges in evaluating the response to immune checkpoint therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are considering or currently undergoing PD-L1 targeted therapies.
Not a fit: Patients with other types of cancer or those who do not have PD-L1 expression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with non-small cell lung cancer.
How similar studies have performed: Previous research has shown promise in using non-invasive techniques for monitoring therapeutic responses, but this specific approach is novel.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Nimmagadda, Sridhar — Johns Hopkins University
- Study coordinator: Nimmagadda, Sridhar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.